Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy - PubMed (original) (raw)
Review
Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy
Christine Odoux et al. Vitam Horm. 2004.
Abstract
In cancer therapy outgrowth of chemoresistant tumor cells is the most important factor that ultimately determines-apart from immediate adverse effects during treatment-the life span and prognosis of cancer patients. Despite many advances in cancer treatment and the integration of supportive medications, including new and better drugs for pain management, antiemesis, infection, and reconstitution of the hematopoietic system, both toxic effects and the development of resistance in response to the treatment remain a major problem. New treatment regimens have to be developed to target cancer more specifically using multiple cellular pathways. This will reduce toxic effects as well as the development of chemoresistance. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is the ligand for death receptors that belong to the TNF death receptor family. TRAIL triggers apoptosis in vitro in various cancer cell types. The antitumor drug, Paclitaxel (PA) was shown to increase the survival of patients with cancer. In in vitro experiments, PA also induces apoptosis in cancer cells. Together, PA and TRAIL lead to tumor regression in in vivo therapy and induce apoptosis through the interaction of TNF family death receptors, caspase activation, and?or cytochrome c release from mitochondria. PA and TRAIL complement each other using two distinct pathways that trigger apoptosis in addition to the anti-microtubule effect of PA. The combination of TRAIL and PA suppresses tumor growth that is otherwise resistant to treatment with either PA or TRAIL alone, by improving proapoptotic effects of the drugs. This observation support the use of the PA and TRAIL in future clinical trials.
Similar articles
- Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Cuello M, et al. Gynecol Oncol. 2001 Jun;81(3):380-90. doi: 10.1006/gyno.2001.6194. Gynecol Oncol. 2001. PMID: 11371126 - TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX, Ogawa O, Kakehi Y. Wu XX, et al. Vitam Horm. 2004;67:365-83. doi: 10.1016/S0083-6729(04)67019-1. Vitam Horm. 2004. PMID: 15110186 Review. - P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR. Park SJ, et al. Biochem Pharmacol. 2006 Jul 28;72(3):293-307. doi: 10.1016/j.bcp.2006.04.024. Epub 2006 May 4. Biochem Pharmacol. 2006. PMID: 16753135 - Modulation of TRAIL signaling for cancer therapy.
Fulda S, Debatin KM. Fulda S, et al. Vitam Horm. 2004;67:275-90. doi: 10.1016/S0083-6729(04)67015-4. Vitam Horm. 2004. PMID: 15110182 Review.
Cited by
- Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules.
Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG. Mielgo A, et al. Oncogene. 2009 Oct 8;28(40):3551-62. doi: 10.1038/onc.2009.210. Epub 2009 Aug 10. Oncogene. 2009. PMID: 19668227 Free PMC article. - To kill a tumor cell: the potential of proapoptotic receptor agonists.
Ashkenazi A, Herbst RS. Ashkenazi A, et al. J Clin Invest. 2008 Jun;118(6):1979-90. doi: 10.1172/JCI34359. J Clin Invest. 2008. PMID: 18523647 Free PMC article. Review.